Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
On Thursday, Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs. Evernorth is a subsidiary of The Cigna Group (NYSE:CI).
Evernorth Health Services周四表示，其Accredo分支机构将向患者提供Humira生物仿制药，无需自付费用。埃弗诺斯是信诺集团（纽约证券交易所代码：CI）的子公司。
Beginning in June, the high- and low-concentration interchangeable biosimilar will be produced for Evernorth's affiliate private-label pharmaceutical distributor, Quallent Pharmaceuticals, through agreements with multiple manufacturers.
从6月开始，通过与多家制造商的协议，将为Evernorth的附属自有品牌药品分销商Qualent Pharmicals生产高浓度和低浓度可互换的生物仿制药。
Most patients will be able to secure the biosimilar products for $0 out-of-pocket through the copay assistance programs offered at Quallent beginning in June, Evernorth said.
埃弗诺斯说，从6月开始，通过Quallent提供的自付额援助计划，大多数患者将能够以0美元的价格获得生物仿制药产品。
This program is estimated to save individual patients around $3,500 on average per year.
据估计，该计划平均每年可为个体患者节省约3500美元。
According to the announcement, the biosimilar price is about 85% lower than that of branded Humira. More than 100,000 Accredo patients use either Humira or one of its biosimilars, the company said.
根据公告，生物仿制药的价格比品牌Humira的价格低约85％。该公司表示，超过10万名Accredo患者使用Humira或其一种生物仿制药。
The specialty pharmacy provides patients with a Therapeutic Resource Center to connect to specialty-trained pharmacists and nurses who are available around the clock. Accredo's centers cover 15 specific conditions.
该专业药房为患者提供治疗资源中心，可与经过专业培训的药剂师和护士建立联系，这些药剂师和护士全天候待命。Accredo 的中心涵盖 15 种特定条件。
Humira is AbbVie Inc's (NYSE:ABBV) blockbuster arthritis drug. In the most recent first-quarter earnings, Humira generated sales of $2.27 billion (down 35.9% Y/Y).
Humira是艾伯维公司（纽约证券交易所代码：ABBV）的重磅关节炎药物。在最新的第一季度财报中，Humira创造了22.7亿美元的销售额（同比下降35.9％）。
Reuters notes that AbbVie has held onto more than 98% of the Humira market despite nine biosimilars being launched in the U.S. last year.
路透社指出，尽管去年在美国推出了九种生物仿制药，但艾伯维仍占据了Humira市场98％以上的份额。
Citing IQVIA data, Reuters highlighted that privately-held German drugmaker Boehringer launched its version, Cyltezo, last July but has only sold a couple of thousand prescriptions since then.
路透社援引IQVIA的数据，强调私人控股的德国制药商勃林格于去年7月推出了其版本Cyltezo，但此后仅售出了几千张处方。
Reuters report added that almost 3 million Humira prescriptions have been written during the same period, although tens of thousands of scripts have started to shift to biosimilar Hyrimoz each week since CVS Health's Inc (NYSE:CVS) pharmacy benefits unit took Humira off the list of drugs it recommends insurers reimburse.
路透社的报道补充说，尽管自CVS Health's Inc（纽约证券交易所代码：CVS）药房福利部门将Humira从其建议保险公司报销的药物清单中删除以来，每周都有成千上万张Humira处方开始转向生物仿制药Hyrimoz，但同期已经开出了近300万张Humira处方。
Price Action: CI shares are down 0.07% at $354.25 at the last check Friday.
价格走势：在周五的最后一次检查中，CI股价下跌0.07％，至354.25美元。
Image: Phoenix Locklear from Pixabay
图片：来自 Pixabay 的菲尼克斯·洛克利尔